Enhancing Donated After Cardiac Death (DCD) Utilization With Thrombolytic Therapy

Completed · Not applicable

Conditions studied: Liver Transplantation, Kidney Transplantation

In brief

We hypothesize that delayed graft function and ITBS events may be related to small blood clots (microthrombi) that collect in the kidneys and liver after cardiac death. Treatment of the DCD organs with a thrombolytic agent prior to implantation may reduce post-transplant morbidity and mortality, and may ultimately result in a greater number of transplantable livers and kidneys.

Key facts

Study ID

NCT01197573

Run by

The Cleveland Clinic

People needed

103

Starts

2010-04-01

Expected to finish

2018-05-01

Last updated by the study team

2018-08-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults aged 18 years and older
• Subjects willing/able to provide written consent
• Subjects willing/able to comply with study requirements
• Subjects who will receive a solitary organ transplant

You may not qualify if…

• Subjects requiring multi-organ transplants
• Women who are pregnant
• Subjects with current severe systemic infection
• Subjects with an active infection

Where it is running

• University Hospitals / Case medical Center — Cleveland, Ohio, United States
• Cleveland Clinic — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.